Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- XTL Biopharmaceuticals Announces Top-Line Results From the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain
Nov 18, 2008 08:05 AM
- Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
Oct 10, 2008 02:00 PM
- XTL Biopharmaceuticals Announces Completion of the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain
Oct 07, 2008 07:35 AM
- XTL Biopharmaceuticals Extraordinary General Meetings Postponed Until October 10, 2008
Oct 02, 2008 11:38 AM
- Notification of Extraordinary General Meetings and Further Changes to Board Composition
Aug 27, 2008 06:24 PM
- XTL Biopharmaceuticals Receives Notice of Non-Compliance With Nasdaq Marketplace Rule Due to Changes in Board Composition
Aug 15, 2008 05:11 PM
- XTL Biopharmaceuticals Announces Appointment of Samuel H. Rudman to Board of Directors
Aug 14, 2008 04:05 PM
- XTL Biopharmaceuticals Announces First Half 2008 Financial Results
Aug 14, 2008 07:35 AM
- XTL Biopharmaceuticals and Presidio Pharmaceuticals Amend License Agreement for Pre-Clinical Hepatitis C Program XTL to Receive Additional $2 Million in Cash in Return for a Reduction in Future Milestones and Royalties
Aug 05, 2008 07:35 AM
- AGM / EGM Statements
Jul 20, 2008 10:28 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
XTLB
|
Compare to S&P
|
| YTD |
-97.19 %
|
-95.40 %
|
| 4 Weeks |
-96.41 %
|
-96.12 %
|
| 12 Weeks |
-98.24 %
|
-97.56 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -0.01 %
|
|
EPS Growth in Last Year: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
